Glenmark Pharma Q4 net benefit falls 26% to ₹173 crore
The organization's merged incomes during the quarter under audit, in any case, rose to ₹3,019 crore as against ₹2,860 crore kept in a similar period keep going year, posting year-on-year development of 6%.
Glenmark Pharmaceuticals Limited on Saturday revealed a net merged benefit of ₹172.6 crore for the quarter finished March 2022 when contrasted with ₹234 crore kept in the comparing time of the last year, enlisting a downfall of 26%.
Notwithstanding, the organization's united incomes during the quarter under survey rose to ₹3,019 crore as against ₹2,860 crore kept in a similar period keep going year, posting year-on-year development of 6%.
For the entire year 2021-22, the organization's net benefit rose to ₹994 crore when contrasted with ₹970 crore kept in the earlier year.
For the year finished March 31, 2022, Glenmark's merged income rose to ₹12,304.9 crore as against ₹10,943.9 crore in the earlier year, recording an increment of 12.4 percent year-on-year.
"We conveyed steady execution consistently and accomplished our key targets, regardless of testing worldwide large scale climate. We had the option to list Glenmark Lifesciences on the Indian Bourses effectively. The out-permitting bargain for ISB 880 with Almirall and US FDA endorsement for Ryaltris, further settled us as the main development driven pharma organization in the nation," said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals.
Post a Comment
Please do not enter any spam links in the comments box.